India's contract development and manufacturing organisation (CDMO) sector is undergoing a sharp hiring realignment toward AI-enabled capabilities, with AI-linked skill demand rising 178 per cent over the past two years, according to a report released on Thursday, 28 May 2025. The findings, published by HR solutions provider CIEL HR, point to a structural shift in how the country's pharmaceutical outsourcing industry is building its workforce.

Key Findings on Hiring Growth

Overall sectoral hiring in the CDMO space rose 52 per cent between 2023 and 2025, the report noted. Within that broader expansion, AI-linked demand climbed from 6.2 per cent to 17.2 per cent of total hiring in 2025. Technology and digital roles recorded the highest AI demand concentration, at nearly 38 per cent.

Notably, the appetite for AI-led skills is no longer confined to traditional tech functions. It is now expanding into core pharmaceutical operations including research and development (R&D), quality assurance, and analytics — roles that have historically been insulated from digital disruption.

Manufacturing Still Dominates, but Growth is Slowing

Despite the digital pivot, manufacturing and operations remained the single largest role segment, accounting for 1,820 positions in 2025. However, this function also posted the slowest year-on-year growth among all role families, at roughly 8 per cent. The report described a momentum shift away from labour intensity toward automation, planning accuracy, and quality predictability — reflecting the rising complexity of outsourced pharmaceutical programmes globally.

A Critical Talent Gap Threatens Execution

The report flagged a widening execution gap between surging AI skill demand and available talent supply, particularly in high-value scientific roles. While demand for AI skills in R&D has reached 24 per cent, the current supply of AI-capable talent in these functions sits below 1 per cent — a mismatch the report described as a significant execution constraint.

The talent deficit is equally stark in manufacturing: out of nearly 1,44,000 manufacturing professionals, only about 0.8 per cent are AI-skilled. In commercial roles, which employ close to 1,19,000 professionals, the figure is even lower at roughly 0.1 per cent. Data and analytics roles showed comparatively higher penetration at approximately 15 per cent.

What Industry Leaders Are Saying

Aditya Narayana Mishra, Managing Director and Chief Executive Officer of CIEL HR, said the sector is entering a transformative phase. 'The CDMO sector is entering a phase where competitive advantage will be the ability to integrate intelligence into every layer of operations. AI is becoming central to how research is accelerated, manufacturing is optimised and client commitments are delivered,' he said.

What This Means for India's Pharma Outsourcing Ambitions

India's CDMO industry has been a beneficiary of global supply chain diversification away from China, with multinational pharmaceutical companies increasingly routing outsourced programmes to Indian players. This comes amid sustained capacity expansion across domestic CDMO firms. However, the talent gap identified in the report suggests that the sector's ability to capture higher-value, intelligence-driven contracts could be constrained unless workforce upskilling is prioritised at scale. The next phase of growth will likely hinge less on manufacturing capacity and more on the ability to deploy AI across research, compliance, and client delivery functions.